L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 202409-33-4 REGISTRY
CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
CN Arcoxia
CN **Etoricoxib**
CN MK 0663
CN MK 663
FS 3D CONCORD
MF C18 H15 Cl N2 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

220 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
223 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 26839-75-8 REGISTRY
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2,5-Thiadiazole, 2-propanol deriv.
CN 2-Propanol, 1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-, (S)-(-)- (8CI)
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-
OTHER NAMES:
CN (-)-S-Timolol
CN (-)-Timolol
CN (S)-Timolol
CN l-Timolol
CN L-Timolol
CN Oftensin
CN **Timolol**
FS STEREOSEARCH
DR 131628-37-0, 194288-09-0
MF C13 H24 N4 O3 S
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1315 REFERENCES IN FILE CA (1907 TO DATE)
  22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1321 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 26921-17-5 REGISTRY
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2,5-Thiadiazole, 2-propanol deriv.
CN 2-Propanol, 1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-, (-)-, maleate (1:1) (salt) (8CI)
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt)
OTHER NAMES:
CN (-)-Timolol maleate
CN (S)-(-)-Timolol maleate
CN (S)-Timolol hydrogen maleate
CN Aquanil
CN Betim
CN Betime
CN Blocadren
CN Blocanol
CN Istalol
CN L-Timolol maleate
CN l-Timolol maleate
CN MK 950
CN Optimol
CN Proflax
CN Rysmon TG
CN Temserin
CN Tenopt
CN Timabak
CN Timacar
CN Timacor
CN Timolol hydrogen maleate
CN Timolol LA
CN **Timolol maleate**
CN Timoptic
CN Timoptol
CN Timoptol XE
CN Timorom
CN WP 934
FS STEREOSEARCH
DR 131628-38-1, 30166-36-0, 116475-10-6
MF C13 H24 N4 O3 S . C4 H4 O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MRCK*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

CM 1

CRN 26839-75-8
CMF C13 H24 N4 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7

B + migr

=> d l11 1-10 bib,kwic

L11 ANSWER 1 OF 10 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1987:233574 BIOSIS
DN PREV198783121744; BA83:121744
TI **TIMOLOL** MALEATE A BETA BLOCKER IN THE TREATMENT OF COMMON **MIGRAINE** HEADACHE.
AU GALLAGHER R M [Reprint author]; STAGLIANO R A; SPORAZZA C
CS MED CENTER FOR HEADACHE, 513 SOUTH LENOLA ROAD, MOORESTOWN, NEW JERSEY 08057, USA
SO Headache, (**1987**) Vol. 27, No. 2, pp. 84-86.
CODEN: HEADAE. ISSN: 0017-8748.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 22 May 1987
Last Updated on STN: 22 May 1987
TI **TIMOLOL** MALEATE A BETA BLOCKER IN THE TREATMENT OF COMMON **MIGRAINE** HEADACHE.
SO Headache, (**1987**) Vol. 27, No. 2, pp. 84-86.
CODEN: HEADAE. ISSN: 0017-8748.
AB **Timolol** maleate, a beta blocker, has been shown to reduce the frequency of common **migraine** headache in clinical trials. An analysis of 116 patients treated prophylactically for common **migraine** with **timolol** maleate 10-30 mg · per day was conducted. There were 35 males and 81 females ranging in age from 19. . . patients (20%) showed < 25% improvement, and 4 patients (3%) discontinued because of side effects. This limited study suggests that **timolol** maleate may be of benefit in the treatment of some **migraine** patients.
RN **26921-17-5** (TIMOLOL MALEATE)

L11 ANSWER 2 OF 10 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1986:431759 BIOSIS
DN PREV198631097571; BR31:97571
TI **TIMOLOL** MALEATE A BETA BLOCKER IN THE TREATMENT OF COMMON **MIGRAINE** HEADACHE.
AU GALLAGHER R M [Reprint author]; STAGLIANO R A
CS MOORESTOWN, NJ, USA
SO Headache, (**1986**) Vol. 26, No. 6, pp. 312.
Meeting Info.: TWENTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE, CHICAGO, ILL., USA, JUNE 27-29, 1986. HEADACHE.
CODEN: HEADAE. ISSN: 0017-8748.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 25 Oct 1986
Last Updated on STN: 25 Oct 1986
TI **TIMOLOL** MALEATE A BETA BLOCKER IN THE TREATMENT OF COMMON **MIGRAINE** HEADACHE.
SO Headache, (**1986**) Vol. 26, No. 6, pp. 312.
Meeting Info.: TWENTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE,. . .
RN **26921-17-5** (TIMOLOL MALEATE)

L11 ANSWER 3 OF 10 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1982:232842 BIOSIS
DN PREV198274005322; BA74:5322

TI BLOCADREN **TIMOLOL** MALEATE IN THE TREATMENT OF **MIGRAINE** PILOT STUDY.
AU LOVLAND B [Reprint author]
CS LOKKEGARDEN LEGEKONTOR, 1400 SKI
SO Tidsskrift for den Norske Laegeforening, (**1981**) Vol. 101, No. 29, pp. 1645-1646.
CODEN: TNLAAH. ISSN: 0029-2001.
DT Article
FS BA
LA NORWEGIAN
TI BLOCADREN **TIMOLOL** MALEATE IN THE TREATMENT OF **MIGRAINE** PILOT STUDY.
SO Tidsskrift for den Norske Laegeforening, (**1981**) Vol. 101, No. 29, pp. 1645-1646.
CODEN: TNLAAH. ISSN: 0029-2001.
AB Patients [23] with **migraine** were, after a wash-out period of 8 wk, treated with blocadren (**timolol** maleate) for 16 wk. Treatment efficacy was primarily evaluated as a reduction in the number of attacks per month and. . .
RN **26921-17-5** (BLOCADREN)
26921-17-5 (TIMOLOL MALEATE)

L11 ANSWER 4 OF 10 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1980:253770 BIOSIS
DN PREV198070046266; BA70:46266
TI THERAPEUTIC USE OF BETA BLOCKERS IN GENERAL PATHOLOGY RHEUMATOLOGY NEUROLOGY AND OPHTHALMOLOGY.
AU BOUVENOT G [Reprint author]; BARTOLIN R; ESCANDE M; DELBOY C
CS SERV MED INTERN, HOTEL DIEU, 13224 MARSEILLE CEDEX 1, FR
SO Therapie (London/Paris), (**1980**) Vol. 35, No. 1, pp. 61-82.
CODEN: THERAP. ISSN: 0040-5957.
DT Article
FS BA
LA FRENCH
SO Therapie (London/Paris), (**1980**) Vol. 35, No. 1, pp. 61-82.
CODEN: THERAP. ISSN: 0040-5957.
AB. . . of Sudek's atrophy and spasmophilia with tachycardia. In neurology, β-blockers are interesting in 60-80% of cases of all types of **migraine**; they decrease the amplitude of senile tremor but they are inactive on the parkinsonian tremor. In ophthalmology, the use of. . .
IT Miscellaneous Descriptors
HUMAN CARDIO VASCULAR SYSTEM **TIMOLOL** MALEATE AUTONOMIC-DRUG OPHTHALMIC-DRUG SUDEKS ATROPHY SPASMOPHILIA TACHY CARDIA **MIGRAINE** SENILE TREMOR PARKINSONIAN TREMOR OPEN ANGLE GLAUCOMA PSYCHIATRY EYE DROP PHARMACODYNAMICS
RN **26921-17-5** (TIMOLOL MALEATE)

L11 ANSWER 5 OF 10 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1998:28538277 BIOTECHNO
TI Report to the Danish committee on adverse drug reactions INDBERETNING TIL BIVIRKNINGSNAEVNET
CS Bivirkningsnaevn, Sundhedsstyrelsen, Frederikssundsvej 387, DK-2700 Bronshoj.
SO Ugeskrift for Laeger, **(23 NOV 1998)**, 160/48 (6996-6998), 20 reference(s)
CODEN: UGLAAD ISSN: 0041-5782
DT Journal; Note
CY Denmark
LA Danish
SO Ugeskrift for Laeger, **(23 NOV 1998)**, 160/48 (6996-6998), 20

reference(s)
CODEN: UGLAAD ISSN: 0041-5782
CT. . . *influenza vaccine; *triamcinolone acetonide; *nevirapine; *nelfinavir; *atovaquone; *imiglucerase; *pramipexole; *lepirudin; *medical society; sodium dihydrogen phosphate; brimonidine; lamivudine; zidometacin; mercaptamine; navelbine; **timolol** maleate; dorzolamide; ibandronic acid; mizolastine; prostavasin; prostaglandin e1; montelukast; hyaluronic acid; grepafloxacin; nefazodone; hydromorphone; verapamil; trandolapril; naratriptan; trandolapril plus verapamil; opidol; naragran; rigidur; cosopt; lamivudine plus zidovudine; phosphoral; sifrol; vertebra fracture; **migraine**; influenza; allergic rhinitis; human immunodeficiency virus infection; asthma; penis disease; hypercalcemia; glaucoma; breast cancer; cystinosis; intraocular hypertension; thrombocytopenia; parkinson disease;. . .
RN. . . 104632-26-0; (lepirudin) 138068-37-8; (sodium dihydrogen phosphate) 7558-80-7, 7632-05-5; (brimonidine) 59803-98-4; (lamivudine) 134678-17-4, 134680-32-3; (zidometacin) 62851-43-8; (mercaptamine) 156-57-0, 60-23-1; (navelbine) 71486-22-1; (**timolol** maleate) **26921-17-5**; (dorzolamide) 130693-82-2; (ibandronic acid) 114084-78-5, 138844-81-2, 138926-19-9; (mizolastine) 108612-45-9; (prostavasin) 55648-20-9; (prostaglandin e1) 745-65-3; (montelukast) 151767-02-1, 158966-92-8; (hyaluronic acid) 31799-91-4,. . .

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:215996 CAPLUS
DN 138:8296
TI Facilitated delivery of timolol maleate by iontophoresis
AU Saraf, Swarnlata; Jain, S.; Dixit, V. K.
CS B.R. Nahata College of Pharmacy, 458 001, India
SO Indian Drugs (**2001**), 38(7), 376-379
CODEN: INDRBA; ISSN: 0019-462X
PB Indian Drug Manufacturers' Association
DT Journal
LA English
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
SO Indian Drugs (**2001**), 38(7), 376-379
CODEN: INDRBA; ISSN: 0019-462X
AB **Timolol** maleate (TM) is a β-adrenergic blocker used in cardiovascular and respiratory complications like hypertension, glaucoma, angina pectoris, myocardial infarction and **migraine**. The iontophoretic technique has been used to enhance the delivery of TM through skin. It is a technique, which permeate ionic form of drugs across the membrane by passing the current through an electrolyte. Iontophoretic delivery of drugs is affected by physico-elec. factors like initial drug concentration, pH, ionic strength, and frequency. These factors were aimed to be optimized for the iontophoretic delivery of TM through the skin. The passive and iontophoretic drug skin permeation studies were conducted by 2-chambered horizontal diffusion cells and human cadaver skin. The iontophoretic permeation through skin was dependent on the ionic species of drug. By optimizing the pH and ionic strength of donor solution and frequency of current the iontophoretic permeability of TM can be enhanced.
IT **26921-17-5**, Timolol maleate
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of timolol maleate by iontophoresis)

L11 ANSWER 7 OF 10 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 96005820 EMBASE
DN 1996005820

TI Medications used to prevent **migraine** headaches and their potential ocular adverse effects.
AU Doughty M.J.; Lyle W.M.
CS Department of Vision Science, Glasgow-Caledonian University, Cowcaddens Road,Glasgow G4 OBA, United Kingdom
SO Optometry and Vision Science, (**1995**) 72/12 (879-891).
ISSN: 1040-5488 CODEN: OVSCET
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
012 Ophthalmology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
TI Medications used to prevent **migraine** headaches and their potential ocular adverse effects.
SO Optometry and Vision Science, (**1995**) 72/12 (879-891).
ISSN: 1040-5488 CODEN: OVSCET
AB . . . present a detailed review of the medications used in the USA, Canada, and the United Kingdom for the prevention of **migraine** and the potential ocular adverse effects associated with the use of these medications. Those drugs that are administered for the purpose of reducing the frequency or severity of **migraine** attacks are classified according to whether they act on the cerebral vasculature primarily at serotonin (5-HT2) receptors (e.g., methysergide, cyproheptadine, and pizotyline), beta adrenergic (primarily beta-2) receptors (e.g., propranolol and **timolol**), via central nervous system (CNS) adrenergic (alpha-2) receptors (e.g., clonidine), or calcium channels (e.g., flunarizine). The roles and mechanisms of action of tricyclic antidepressants (e.g., amitriptyline) and non-steroidal anti-inflammatory drugs (NSAIDs) in the prophylactic management of **migraine** are also discussed, along with possible pharmacogenetic differences in the kinetics of action of some of these drugs. The general. . .
CT Medical Descriptors:
*eye disease: ET, etiology
*eye disease: SI, side effect
***migraine: PC, prevention**
***migraine: DT, drug therapy**
article
conjunctivitis: SI, side effect
diet
diplopia: SI, side effect
drug contraindication
drug mechanism
drug safety
dry eye: SI, side effect
food composition
gastrointestinal symptom: SI, side. . .
RN. . . . 21829-25-4; (phenethylamine) 64-04-0; (pizotifen) 15574-96-6; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (reserpine) 50-55-5, 8001-95-4; (serotonin) 50-67-9; (timolol) 26839-75-8; (timolol maleate) **26921-17-5**; (tryptamine) 343-94-2, 61-54-1; (tyramine) 51-67-2, 60-19-5

L11 ANSWER 8 OF 10 EMBASE
on STN
AN 85050077 EMBASE
DN 1985050077
TI [Antimigraine agents].
ANTIMIGRAINEUX.
AU Rascol A.; Fanchamps A.

CS Service de Neurologie, CHU Purpan, 31059 Toulouse Cedex, France
SO Semaine des Hopitaux, (**1984**) 60/44-45 (3137-3161).
CODEN: SHPAAI
CY France
DT Journal
FS 038 Adverse Reactions Titles
037 Drug Literature Index
008 Neurology and Neurosurgery
030 Pharmacology
LA French
SL English
SO Semaine des Hopitaux, (**1984**) 60/44-45 (3137-3161).
CODEN: SHPAAI
AB The definition of **migraine** proposed by the ad hoc committee in its classification of the different forms of headache is the most widely accepted. In this chapter, currently established physiopathological mechanisms of **migraine** attacks with the different stages of encephalic vasomotor disorders and the humoral changes which produce them are exposed. A description is given of the as yet incompletely understood constitutional anomalies that predispose to **migraine**; these include platelet function disorders currently considered as central, but also other factors such as hypersensitivity to dopamine or alterations. . . complied with. Ergot toxicity is usually the result of excessive dosage or overprolonged use. The chapter on maintenance therapy of **migraine** addresses only the most widely used drugs whose effectiveness has been established by controlled trials. Such drugs are numerous, have. . . stabilizers of vascular tone (dihydroergotamine, clonidine, flunarizine), substances that interfere with serotonin (methysergide, pizotifen, dimetotiazine, oxetorone), beta blocking agents (propranolol, **timolol**), platelet aggregation inhibitors (acetylsalicylic acid, dipyramidole), antidepressants (tricyclic antidepressants, lithium). Maintenance treatment is justified only if attacks recur frequently and. . .
CT Medical Descriptors:
*adverse drug reaction
*artery spasm
*drug interaction
migraine
*pharmacokinetics
*drug therapy
peripheral vascular system
muscle
therapy
human
central nervous system
*acebutolol
*acetylsalicylic acid
*alprenolol
*aminophenazone
*amitriptyline
*antimigraine agent
*atenolol
*beta adrenergic receptor blocking agent
*caffeine
*clomipramine
*clonidine
*dexpropranolol
*dihydroergotamine mesilate
*dimetotiazine
*ergotamine
*ergotamine tartrate
*flufenamic acid

*flunarizine
*imipramine
*lithium carbonate
*mefenamic acid
*methysergide
*metoprolol
*nadolol
*oxetorone
*oxprenolol
*phenacetin
*pindolol
*pizotifen
*practolol
*propranolol
*propyphenazone
*timolol
anticoagulant agent
antihypertensive agent
tuberculostatic agent
cholinergic. . .

RN. . . 363-24-6; (quinidine) 56-54-2; (sulfinpyrazone) 57-96-5; (troleandomycin) 2751-09-9; (tyramine) 51-67-2, 60-19-5; (verapamil) 152-11-4, 52-53-9; (dipyridamole) 58-32-2; (oxetorone fumarate) 34522-46-8; (timolol maleate) **26921-17-5**; (pizotifen maleate) 24359-22-6; (dimetotiazine mesylate) 13115-40-7

L11 ANSWER 9 OF 10 EMBASE
on STN
AN 85011557 EMBASE
DN 1985011557
TI **Migraine** prevention with **timolol**. A double-blind crossover study.
AU Stellar S.; Ahrens S.P.; Meibohm A.R.; Reines S.A.
CS Department of Neurosurgery, St Barnabas Medical Center, Livingston, NJ 07039, United States
SO Journal of the American Medical Association, (**1984**) 252/18 (2576-2580).
CODEN: JAMAAP
CY United States
DT Journal
FS 038 Adverse Reactions Titles
037 Drug Literature Index
008 Neurology and Neurosurgery
030 Pharmacology
LA English
TI **Migraine** prevention with **timolol**. A double-blind crossover study.
SO Journal of the American Medical Association, (**1984**) 252/18 (2576-2580).
CODEN: JAMAAP
AB One hundred seven patients (77 women and 30 men) with **migraine** headache were given prophylactic treatment with **timolol** maleate, 20 to 30 mg/day, or matching placebo during a 20-week, double-blind crossover study. Among the 94 patients who completed the study, **timolol** was significantly better than placebo in terms of a decrease in frequency of headaches from baseline, numbers of patients who had a 50% reduction in headache frequency, global response, and patient preference. Overall global response rates were 65% with **timolol** compared with 40% with placebo. The severity and duration of headaches that occurred were unchanged. Few side effects were reported with either **timolol** or placebo. The study demonstrates that the β-blocker **timolol** is a safe and effective treatment in patients with

frequent **migraine** headaches.

CT Medical Descriptors:
*adverse drug reaction
*constipation
*drug efficacy
*fatigue
*gastrointestinal toxicity
*insomnia
***migraine**
*neurotoxicity
*drug therapy
*stomach pain
*vertigo
prevention
priority journal
large intestine
stomach
therapy
intoxication
nervous system
oral drug administration
human
central nervous system
controlled study
major clinical study
*timolol
*timolol maleate
acetylsalicylic acid
butalbital
caffeine
ergotamine
paracetamol
placebo

RN (timolol) 26839-75-8; (timolol maleate) **26921-17-5**; (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (butalbital) 51005-25-5, 77-26-9; (caffeine) 30388-07-9, 58-08-2; (ergotamine) 113-15-5, 52949-35-6; (paracetamol) 103-90-2

L11 ANSWER 10 OF 10 EMBASE
on STN
AN 83065958 EMBASE
DN 1983065958
TI The prophylactic effect of **timolol** versus propranolol and placebo in common **migraine**: Beta-blockers in **migraine**.
AU Standnes B.
CS Neurol. Dep., Ulleval Hosp., Oslo 1, Norway
SO Cephalalgia, (**1982**) 2/3 (165-170).
CODEN: CEPHDF
CY Norway
DT Journal
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
TI The prophylactic effect of **timolol** versus propranolol and placebo in common **migraine**: Beta-blockers in **migraine**.
SO Cephalalgia, (**1982**) 2/3 (165-170).
CODEN: CEPHDF
AB A multicentre double-blind, cross-over trial was planned to evaluate the prophylactic effect of **timolol** in **migraine**. The effectiveness of the drug was compared to propranolol and placebo. In the Norwegian part of the trial described in this paper, 18 patients completed the study. The data suggest that **timolol** is equivalent in

effectiveness to propranolol in **migraine** prophylaxis. Firm conclusions should not be drawn until the results from the multicentre trial are available.

CT Medical Descriptors:
*headache
***migraine**
*drug therapy
therapy
human
central nervous system
prevention
clinical article
*placebo
*propranolol
*timolol
timolol maleate

RN (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (timolol) 26839-75-8; (timolol maleate) **26921-17-5**

```
     (FILE 'HOME' ENTERED AT 14:41:54 ON 15 DEC 2004)

     FILE 'REGISTRY' ENTERED AT 14:42:04 ON 15 DEC 2004
L1             1 S ETORICOXIB/CN
L2             1 S TIMOLOL/CN
L3             1 S (TIMOLOL MALEATE)/CN

     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT,
     CAPLUS, CEN, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL,
     EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS,
     KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 14:43:14
     ON 15 DEC 2004
L4             3 S L1 AND L3
L5            62 S L1 AND MIGRAINE
L6            15 S L5 AND PD<2003
L7            14 DUP REM L6 (1 DUPLICATE REMOVED)
L8            94 S L3 AND MIGRAINE
L9            78 S L8 AND PD<2003
L10           74 DUP REM L9 (4 DUPLICATES REMOVED)
L11           10 S L10 AND (TIMOLOL (P) MIGRAINE)

=>
```

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:314539 CAPLUS
DN 132:329940
TI Pharmaceutical compositions containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment
IN Simitchieva, Kremena; Reines, Scott A.; Mckinney, Errol; Sandquist, Eric J.; Khanna, Deepak K.; Hargreaves, Richard
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000025779	A1	20000511	WO 1999-US25388	19991029
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2348979	AA	20000511	CA 1999-2348979	19991029
	EP 1126841	A1	20010829	EP 1999-960171	19991029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002528498	T2	20020903	JP 2000-579220	19991029
	AU 759307	B2	20030410	AU 2000-17098	19991029
	US 2002016348	A1	20020207	US 2001-934823	20010822
	US 6384034	B2	20020507		
	US 2002177617	A1	20021128	US 2002-106845	20020326
PRAI	US 1998-106605P	P	19981102		
	US 1999-429274	A1	19991029		
	WO 1999-US25388	W	19991029		
	US 2001-934823	A3	20010822		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Pharmaceutical compositions containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment

AB A combination of a 5HT1B/1D agonist and a cyclooxygenase-2 (COX-2) selective inhibitor is useful in the treatment and/or prevention of **migraine**. The 5HT1B/1D agonist is selected from sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, and rizatriptan, and the COX-2 inhibitor is selected from meloxicam, **MK-663**, Vioxx, RS 57067, celecoxib, and compound I. The 5HT1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form or as sep. dosage forms administered concurrently. Tablets containing 5 and 10 mg of rizatriptan benzoate and 10 mg Vioxx were prepared

ST cyclooxygenase inhibitor histaminergic agonist tablet **migraine**

IT 5-HT agonists
(5-HT1B; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 5-HT agonists
(5-HT1D; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT Antimigraine agents
(tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT Drug delivery systems
(tablets; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 39391-18-9, Cyclooxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, inhibitors; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 71125-38-7, Meloxicam 103628-46-2, Sumatriptan 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 145202-66-0, Rizatriptan benzoate 154323-57-6, Almotriptan 162011-90-7, Vioxx 169590-42-5, Celecoxib 179382-91-3, RS 57067 180200-69-5 202409-33-4, **MK 663**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

=>

MG + COX2

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:260861 CAPLUS
DN 138:276275
TI Cyclooxygenase-2 inhibitor compositions with rapid onset of therapeutic effect
IN Kararli, Tugrul T.; Kontny, Mark J.; Desai, Subhash; Hageman, Michael J.; Haskell, Royal J.; Hassan, Fred; Forbes, James C.
PA USA
SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 731,350.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003064098	A1	20030403	US 2001-874504	20010605
	US 2002142045	A1	20021003	US 2002-113157	20020401 <--
PRAI	US 1999-169856P	P	19991209		
	US 2000-731350	A2	20001206		
	US 2000-31898	A2	20001206		
	WO 2000-US32434	W	20001206		
	US 2001-874504	A1	20010605		

OS MARPAT 138:276275

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003064098	A1	20030403	US 2001-874504	20010605
	US 2002142045	A1	20021003	US 2002-113157	20020401 <--

IT Headache
(**migraine**; cyclooxygenase-2 inhibitor compns. with rapid onset of therapeutic effect)
IT 58-08-2, Caffeine, biological studies 58-55-9, Theophylline, biological studies 69-89-6D, Xanthine, alkyl derivs. 83-67-0, Theobromine 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 181695-72-7, Valdecoxib **202409-33-4** 212126-32-4 215123-80-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor compns. with rapid onset of therapeutic effect)

L7 ANSWER 2 OF 14 USPATFULL on STN DUPLICATE 1
AN 2002:27500 USPATFULL
TI Method of treating migraines and pharmaceutical compositions
IN Simitchieva, Kremena, Basking Ridge, NJ, UNITED STATES
Reines, Scott A., New Hope, PA, UNITED STATES
Mckinney, Errol, Doylestown, PA, UNITED STATES
Sandquist, Eric J., Doylestown, PA, UNITED STATES
Khannna, Deepak K., Furlong, PA, UNITED STATES
Hargreaves, Richard, Terlings Park, UNITED KINGDOM
PA Merck & Co. Inc. (U.S. corporation)
PI US 2002016348 A1 20020207 <--
US 6384034 B2 20020507
AI US 2001-934823 A1 20010822 (9)
RLI Continuation of Ser. No. US 1999-429274, filed on 29 Oct 1999, PENDING
PRAI US 1998-106605P 19981102 (60)
DT Utility
FS APPLICATION
LREP RICHARD C. BILLUPS, Patent Department, Merck & Co. Inc., P.O. Box 2000, Rahway, NJ, 07065-0907
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 331

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002016348 A1 20020207 <--
US 6384034 B2 20020507

AB A combination of a 5HT.sub.1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of **migraine**.

SUMM . . . has been known for some time that sumatriptan, which causes constriction of cranial blood vessels, is an effective treatment for **migraine** (see, for example, Doenicke et al., Lancet, 1988, Vol. 1, 1309-11; and Feniuk & Humphrey, Drug Development Research, 1992, 26,. . .

SUMM . . . within the trigeminal nucleus caudalis. It is believed that one or more of these three mechanisms is involved in the anti-**migraine** action of 5-HT.sub.1B/1D receptor agonists such as rizatriptan.

SUMM . . . method of treating or preventing migraines in a mammalian patient in need thereof, which comprises administering to said patient an anti-**migraine** effective amount of a combination of a COX-2 selective inhibitor and a 5-HT.sub.1B/1D receptor agonist.

SUMM [0011] One embodiment of the present invention is a method of treating or preventing **migraine** with an anti-**migraine** effective amount of a combination of a 5HT.sub.1B/1D agonist and a COX-2 selective inhibitor.

SUMM [0017] In one aspect of the invention, a method of treating or preventing **migraine** is disclosed in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective. . .

SUMM [0026] An anti-**migraine** effective amount of the combination is that amount that will relieve the subject being treated of the symptoms of the **migraine** attack and the specific dose level and frequency of dosage may vary and will depend upon a variety of factors. . .

SUMM [0027] For the treatment of a **migraine** attack, the active ingredients, separately or in combination, may be administered orally, topically, parenterally, by inhalation, spray, rectally or intravaginally. . .

CLM What is claimed is:
1. A method of treating or preventing **migraine** in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective inhibiting compound. . .

IT 71125-38-7, Meloxicam 103628-46-2, Sumatriptan 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 145202-66-0, Rizatriptan benzoate 154323-57-6, Almotriptan 162011-90-7, Vioxx 169590-42-5, Celecoxib 179382-91-3, RS 57067 180200-69-5 **202409-33-4**, MK 663
(tablets containing histaminergic agonist and COX-2 inhibitor for migraine treatment)

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964146 CAPLUS
DN 138:39187
TI Preparation of piperidinecarboxylates and related compounds as NMDA NR2B receptor antagonists for the treatment or prevention of **migraine**
.
IN Allen, Christopher; Koblan, Ken S.; Sleeth, Timothy
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2002100352 A2 20021219 WO 2002-US21069 20020607 <--
WO 2002100352 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1399160 A2 20040324 EP 2002-744807 20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004204341 A1 20041014 US 2003-479923 20031205
PRAI US 2001-297672P P 20010612
WO 2002-US21069 W 20020607

TI Preparation of piperidinecarboxylates and related compounds as NMDA NR2B receptor antagonists for the treatment or prevention of **migraine**

.

PI WO 2002100352 A2 **20021219**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100352	A2	20021219	WO 2002-US21069	20020607 <--
WO 2002100352	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1399160	A2	20040324	EP 2002-744807	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004204341	A1	20041014	US 2003-479923	20031205

ST piperidinecarboxylate prepn NR2B receptor antagonist; **migraine** treatment piperidinecarboxylate prepn

IT 5-HT agonists
(5-HT1B, coadministration; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 5-HT agonists
(5-HT1D, coadministration; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT Calcitonin gene-related peptide receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ligands, coadministration; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT Headache
(**migraine**, treatment; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT Antimigraine agents
Human
(preparation of piperidinecarboxylates and related compds. as NR2B receptor

antagonists for the treatment or prevention of **migraine**)

IT Glutamate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 103628-46-2, Sumatriptan 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 154323-57-6, Almotriptan 158966-92-8, Montelukast 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 180200-68-4, JTE522 181695-72-7, Valdecoxib 197438-48-5, BMS347070 198470-84-7, Parecoxib **202409-33-4**, Etoricoxib 220991-20-8, COX 189 221148-46-5 266320-83-6, ABT 963 346670-87-9, CS 502 (pharmaceutical)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 455265-37-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 366022-97-1P 455265-19-7P, Benzyl 4-[(4-pyridinylamino)methyl]-1-piperidinecarboxylate 455265-20-0P, Benzyl 4-[[(3-pyridinyl)amino]methyl]-1-piperidinecarboxylate 455265-21-1P, Benzyl 4-[(3-isoxazolylamino)methyl]-1-piperidinecarboxylate 455265-23-3P 455265-24-4P 455265-25-5P, 4-[(3-Methylpyridin-4-ylamino)methyl]piperidine-1-carboxylic acid benzyl ester 455265-27-7P, Benzyl 4-[[(4-methyl-2-pyridinyl)amino]methyl]-1-piperidinecarboxylate 455265-28-8P, Benzyl 4-[(1,3,4-thiadiazol-2-ylamino)methyl]-1-piperidinecarboxylate 455265-30-2P 455265-31-3P 455265-32-4P, Benzyl 4-[[(2-pyridinyl)amino]methyl]-1-piperidinecarboxylate 455265-33-5P, Benzyl 4-[[(4-ethyl-2-pyridinyl)amino]methyl]-1-piperidinecarboxylate 455265-34-6P, Benzyl 4-[[(1-oxido-4-pyridinyl)amino]methyl]-1-piperidinecarboxylate 455265-35-7P 455265-36-8P 455265-38-0P
455265-39-1P 455265-40-4P 455265-41-5P 455265-42-6P 455265-44-8P
455265-45-9P 455265-46-0P 455265-48-2P 455265-49-3P 455265-51-7P
455265-52-8P 455265-54-0P 455265-55-1P 455265-56-2P 455265-57-3P
455265-58-4P 455265-59-5P 455265-60-8P 455265-61-9P 455265-62-0P
455265-63-1P 455265-64-2P 455265-66-4P 455265-67-5P 455265-68-6P
455265-69-7P 455265-70-0P 455265-71-1P 455265-73-3P 455265-74-4P
455265-75-5P 455265-76-6P 455265-77-7P 455265-78-8P 455265-79-9P
455265-80-2P 455265-81-3P 455265-82-4P 455265-83-5P 455265-84-6P
455265-85-7P 455265-86-8P 455265-87-9P 455265-88-0P 455265-89-1P
455265-90-4P 455265-91-5P 455265-92-6P 455265-93-7P 455265-94-8P
455265-95-9P 455265-96-0P 455265-97-1P 455265-98-2P 455265-99-3P
455266-00-9P 455266-01-0P 455266-03-2P 455266-04-3P 455266-05-4P
455266-06-5P 455266-07-6P 455266-08-7P 455266-09-8P 455266-10-1P
455266-11-2P 455266-12-3P 455266-14-5P 455266-15-6P 455266-16-7P
455266-17-8P 455266-18-9P 455266-19-0P 455266-20-3P 455266-21-4P
455266-22-5P 455266-23-6P 455266-25-8P 455266-26-9P 455266-27-0P
455266-28-1P 455266-29-2P 455266-98-5P 455267-13-7P 455267-18-2P
455267-73-9P 455267-78-4P 455267-79-5P 455267-93-3P 455267-94-4P
455267-96-6P 455267-97-7P, 3-[(Pyrimidin-2-ylamino)methyl]pyrrolidine-1-carboxylic acid benzyl ester 455268-07-2P 455290-06-9P, Benzyl 4-[[(5-methyl-2-pyridinyl)amino]methyl]-1-piperidinecarboxylate
455290-15-0P 471248-53-0P, 4-[(4-Hydroxybenzoylamino)methyl]piperidine-1-carboxylic acid benzyl ester 471248-54-1P 471248-55-2P 471248-56-3P
471248-57-4P 471248-58-5P 471248-59-6P 471248-60-9P 471248-61-0P
471248-62-1P 471248-63-2P 471248-64-3P 471248-65-4P 471248-66-5P
471248-67-6P 471248-68-7P 471248-69-8P 471248-70-1P 471248-71-2P
471248-72-3P 471248-73-4P 471248-74-5P 471248-75-6P 471248-76-7P

471248-77-8P 471248-78-9P 471248-79-0P 471248-80-3P 471248-81-4P
471248-82-5P 471248-83-6P 471248-84-7P 471248-85-8P 471248-86-9P
471248-87-0P 471248-88-1P 471248-89-2P 471248-90-5P 471248-91-6P
471248-92-7P 471248-93-8P 471248-94-9P 471248-95-0P 471248-96-1P
471248-97-2P 471248-98-3P 471248-99-4P 471249-00-0P 471249-01-1P
471249-02-2P 471249-03-3P 471249-04-4P 471249-05-5P 471249-06-6P
471249-07-7P 471249-08-8P 471249-09-9P 471249-10-2P 471249-11-3P
471249-12-4P 471249-13-5P 471249-14-6P 471249-15-7P 471249-16-8P
471249-17-9P 471249-19-1P 471249-21-5P 471249-22-6P 471249-23-7P
471249-24-8P 471249-26-0P 471249-27-1P 471249-28-2P 471249-29-3P
471249-30-6P 471249-31-7P 471249-32-8P 471249-33-9P 471249-34-0P
471249-35-1P 471249-36-2P 471249-37-3P 471249-38-4P 471249-39-5P
471249-40-8P 471249-41-9P 471249-42-0P 471249-43-1P 471249-44-2P
471249-45-3P 471249-46-4P 471249-47-5P 471249-48-6P 471249-49-7P
471249-50-0P 471249-51-1P 471249-52-2P 471249-53-3P 471249-54-4P
471249-55-5P 471249-56-6P 471249-57-7P 471249-58-8P 471249-59-9P
471249-60-2P 471249-61-3P 471249-62-4P 471249-63-5P 471249-64-6P
471249-65-7P 471249-66-8P 471249-67-9P 471249-68-0P 471249-69-1P
471249-70-4P 471249-71-5P 471249-72-6P 471249-73-7P 471249-74-8P
471249-75-9P 471249-76-0P 471249-77-1P 471249-78-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 471249-80-6P 471249-81-7P 471249-82-8P 471249-83-9P 471249-84-0P
471249-85-1P 471249-86-2P 471249-87-3P 471249-88-4P 471249-89-5P
471249-90-8P 471249-91-9P 471249-92-0P 471249-93-1P 471249-94-2P
471249-95-3P 471249-96-4P 471249-97-5P 471249-98-6P 471249-99-7P
471250-00-7P 471250-01-8P 471250-02-9P 471250-03-0P 471250-04-1P
471250-05-2P 471250-06-3P 471250-07-4P 471250-08-5P 471250-09-6P
471250-10-9P 471250-11-0P 471250-12-1P 471250-13-2P 471250-14-3P
471250-15-4P 471250-17-6P 471250-18-7P 471250-19-8P 471250-21-2P
471250-22-3P 471250-24-5P 471250-26-7P 471250-27-8P 471250-28-9P
471250-29-0P 471250-30-3P 471250-31-4P 471250-33-6P 471250-34-7P
471250-35-8P 471250-36-9P 471250-37-0P 471250-38-1P 471250-39-2P
471250-40-5P 471250-41-6P 471250-42-7P 471250-43-8P 471250-44-9P
471250-45-0P 471250-46-1P 471250-47-2P 471250-48-3P 471250-49-4P
471250-50-7P 471250-51-8P 471250-52-9P 471250-53-0P 471250-54-1P
471250-55-2P 471251-14-6P 471252-58-1P 471257-73-5P 471257-74-6P
471257-75-7P 471257-76-8P 478552-66-8P 478552-68-0P, Benzyl 4-[[(1-methyl-1H-imidazol-2-yl)amino]methyl]-1-piperidinecarboxylate 478552-69-1P, 4-(Quinolin-2-ylaminomethyl)piperidine-1-carboxylic acid benzyl ester 478552-71-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 51-21-8, 5-Fluorouracil 55-22-1, Isonicotinic acid, reactions 87-42-3, 6-Chloropurine 96-50-4, 2-Aminothiazole 99-96-7, 4-Hydroxybenzoic acid, reactions 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 100-54-9, 3-Cyanopyridine 104-53-0, Benzenepropanal 108-00-9, N,N-Dimethylethylenediamine 122-59-8, Phenoxyacetic acid 123-38-6, Propionaldehyde, reactions 141-30-0, 3,6-Dichloropyridazine 155-10-2, 2-Chloro-5-fluoropyrimidin-4-ylamine 372-48-5, 2-Fluoropyridine 456-47-3, 3-Fluorobenzyl alcohol 462-08-8, 3-Aminopyridine 499-80-9, 2,4-Pyridinedicarboxylic acid 501-52-0, 3-Phenylpropionic acid 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 578-68-7, 4-Aminoquinoline 622-78-6, Benzyl isothiocyanate 626-60-8, 3-Chloropyridine 626-61-9, 4-Chloropyridine 645-45-4, Hydrocinnamoyl chloride 676-58-4, Methylmagnesium chloride

695-34-1, 2-Amino-4-methylpyridine 699-02-5, 2-(4-Methylphenyl)ethanol
932-22-9 1120-87-2, 4-Bromopyridine 1193-21-1, 4,6-Dichloropyrimidine
1450-93-7, 2-Aminoimidazole hemisulfate 1603-40-3, 2-Amino-3-
methylpyridine 1603-41-4, 2-Amino-5-methylpyridine 1681-15-8
1722-12-9, 2-Chloropyrimidine 1750-42-1, 3-Aminoisoxazole 1780-31-0,
2,4-Dichloro-5-methylpyrimidine 1875-88-3, 2-(4-Chlorophenyl)ethanol
1990-90-5, 4-Amino-3-methylpyridine 2346-74-9 2932-58-3,
2-(2-Fluorophenyl)ethanol 3173-56-6, Benzyl isocyanate 3430-10-2,
3-(2-Aminomethyl)pyridine 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-
d]pyrimidine 3796-23-4, 3-Trifluoromethylpyridine 3934-20-1,
2,4-Dichloropyrimidine 4005-51-0, 2-Amino-1,3,4-thiadiazole 4331-29-7,
1H-Benzimidazol-4-ylamine 4436-24-2, 2-Benzyloxirane 4595-60-2,
2-Bromopyrimidine 4653-11-6, 4-Thiophen-2-ylbutyric acid 4858-85-9,
2,3-Dichloropyrazine 5049-61-6, Aminopyrazine 5424-21-5,
2,4-Dichloro-6-methylpyrimidine 5440-17-5 5470-22-4, 4-Chloropicolinic
acid 5685-38-1, 2-Phenylcyclopropanecarboxylic acid 6094-60-6,
1-Benzyl-4-hydroxypiperidine-4-carbonitrile 6966-78-5,
4-Methylthiopteridine 6980-11-6, 7-Chloro-3H-imidazo[4,5-b]pyridine
7144-05-0, 4-Aminomethylpiperidine 7461-50-9, 2-Chloropyrimidin-4-
ylamine 7589-27-7, 2-(4-Fluorophenyl)ethanol 10310-21-1 10314-98-4,
1-[(Benzyloxy)carbonyl]-4-piperidinecarboxylic acid 10387-40-3,
Potassium thioacetate 13036-57-2, 2-Chloro-4-methylpyrimidine
13139-17-8 13534-90-2, 3,4-Dibromopyridine 17012-21-4 19524-06-2,
4-Bromopyridine hydrochloride 20781-20-8, 2,4-Dimethoxybenzylamine
20928-46-5 22282-75-3, 3-Fluoro-4-iodopyridine 22536-61-4,
2-Chloro-5-methylpyrimidine 22536-66-9, 2-Chloropyrimidine-4-carboxylic
acid amide 22990-77-8, 2-Aminomethylpiperidine 23719-80-4,
Cyclopropylmagnesium bromide 24225-89-6, 1,4-Dibenzyl-2-
chloromethylpiperazine 27048-04-0, 6-Chloro-3-nitropyridin-2-ylamine
33252-32-3, 2-Amino-4-ethylpyridine 34271-31-3, (trans)-2-
Phenylcyclopropanecarboxaldehyde 39514-19-7, Ethyl N-benzyl-3-
oxopiperidine-4-carboxylate 49844-90-8, 4-Chloro-2-methylthiopyrimidine
51171-02-9, 3-Bromopyrazine-2-carboxylic acid methyl ester 51934-41-9,
Ethyl 4-iodobenzoate 52147-97-4 52334-53-9, 4-Aminopyridin-3-ol
52763-21-0, Ethyl N-benzyl-3-oxopiperidine-4-carboxylate hydrochloride
59870-43-8, 2-Chloroquinazolin-4-ylamine 65853-61-4,
N-[(4-Chlorobenzyloxy)carbonyloxy]succinimide 71637-34-8,
Thiophen-3-ylmethanol 79521-61-2 110105-91-4, N-(4-Piperidinylmethyl)-
4-pyridinamine 110859-47-7 128595-01-7 138163-08-3, Benzyl
4-formyl-1-piperidinecarboxylate 148148-48-5 179322-60-2,
2-tert-Butoxycarbonylaminopyrimidine-5-carboxylic acid 332378-21-9,
N-[(4-Fluorobenzyloxy)carbonyloxy]succinimide 455267-67-1,
4-Methylbenzyl 4-(aminomethyl)-1-piperidinecarboxylate 455267-72-8
455267-76-2 455267-77-3, 4-Fluorobenzyl 4-(aminomethyl)piperidine-1-
carboxylate 455267-80-8 455267-81-9 471254-19-0,
1H-Pyrazole-4-carboxylic acid (piperidin-4-ylmethyl)amide 471254-20-3,
4-Hydroxy-N-piperidin-4-ylmethylbenzamide 471254-22-5 478552-73-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor
antagonists for the treatment or prevention of **migraine**)

IT 332-43-4P, 1-(2-Chloroethyl)-4-fluorobenzene 2927-71-1P,
2,4-Dichloro-5-fluoropyrimidine 14161-11-6P, 3,4,5-Trichloropyridazine
21908-08-7P, 2-Formylisonicotinic acid ethyl ester 23504-39-4P,
2-(Diethyloxymethyl)isonicotinic acid ethyl ester 23804-68-4P,
4-Aminomethyl-1-benzylpiperidin-4-ol 35391-85-6P, 4-Cyclopropylbenzoic
acid ethyl ester 39478-61-0P, 1-Benzyl-4-hydroxymethylpiperidin-3-ol
41438-38-4P, 2,4-Pyridinedicarboxylic acid diethyl ester 62802-42-0P,
2-Chloro-5-fluoropyrimidine 85151-16-2P 110105-32-3P, Benzyl
4-[(4-pyridinylamino)carbonyl]-1-piperidinecarboxylate 110105-98-1P
115687-29-1P, 1-Benzylpyrrolidine-3-carboxylic acid amide 116163-33-8P
132431-09-5P 135632-53-0P 144222-22-0P, 4-Aminomethylpiperidine-1-
carboxylic acid tert-butyl ester 155456-33-0P 157023-34-2P, Benzyl

4-(aminomethyl)piperidine-1-carboxylate 160809-34-7P, 4-Acetylpiperidine-1-carboxylic acid benzyl ester 172348-56-0P 177948-01-5P 177948-02-6P 191150-86-4P 191150-87-5P, (cis)-3-Hydroxy-4-hydroxymethylpiperidine-1-carboxylic acid benzyl ester 315717-77-2P, 3-Aminomethylpyrrolidine-1-carboxylic acid benzyl ester 405219-34-3P 454678-87-6P, (4-Cyclopropylphenyl)methanol 455265-50-6P 455267-05-7P, Benzyl 4-[[(1-oxido-4-pyridinyl)amino]carbonyl]-1-piperidinecarboxylate 455267-06-8P 455267-07-9P, (cis)-3-Hydroxy-4-[(2,3,5,6-tetrachloropyridin-4-ylamino)methyl]piperidine-1-carboxylic acid benzyl ester 455267-08-0P 455267-12-6P 455267-14-8P 455267-15-9P 455267-17-1P 455267-19-3P 455267-21-7P 455267-22-8P 455267-23-9P 455267-24-0P 455267-26-2P, 3-Carbamoylpyrrolidine-1-carboxylic acid benzyl ester 455267-27-3P 455267-28-4P 455267-29-5P 455267-30-8P 455267-31-9P 455267-32-0P 455267-33-1P 455267-35-3P 455267-36-4P 455267-37-5P 455267-38-6P 455267-39-7P 455267-40-0P 455267-41-1P 455267-42-2P 455267-43-3P 455267-69-3P 455267-71-7P, (cis)-4-[(Pyridin-4-ylamino)methyl]piperidin-3-ol 455267-74-0P, 3-[(Piperidin-4-ylmethyl)amino]pyrazin-2-ol 471254-06-5P, 2-(Diethyloxymethyl)isonicotinic acid 471254-07-6P 471254-09-8P 471254-11-2P 471254-12-3P, 3-Hydroxy-4-hydroxymethylpiperidine-1-carboxylic acid benzyl ester 471254-13-4P, 4-Hydroxy-N-pyridin-3-ylmethylbenzamide 471254-14-5P, 4-Hydroxy-N-piperidin-3-ylmethylbenzamide 471254-15-6P, 2-Azidomethyl-1,4-dibenzylpiperazine 471254-16-7P, N-(1,4-Dibenzylpiperazin-2-ylmethyl)-4-hydroxybenzamide 471254-17-8P, 4-Hydroxy-N-piperazin-2-ylmethylbenzamide 471254-18-9P, N-(4-Benzylmorpholin-2-ylmethyl)-4-hydroxybenzamide 478552-70-4P 478552-72-6P, (trans)-3-Hydroxy-4-hydroxymethylpiperidine-1-carboxylic acid benzyl ester 478552-74-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

IT 329900-75-6, Cyclooxygenase-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective inhibitors, coadministration; preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:868732 CAPLUS
DN 137:363084
TI Use of cyclooxygenase inhibitors for treating migraines
IN Allen, Christopher; Stone, Phyllis; Harper, Sean
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089798	A2	20021114	WO 2002-US13750	20020430 <--
WO 2002089798	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1423114 A2 20040602 EP 2002-731606 20020430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004132780 A1 20040708 US 2003-476753 20031103
PRAI US 2001-288623P P 20010504
WO 2002-US13750 W 20020430
PI WO 2002089798 A2 **20021114**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002089798	A2	20021114	WO 2002-US13750	20020430 <--
WO 2002089798	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1423114 A2 20040602 EP 2002-731606 20020430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004132780 A1 20040708 US 2003-476753 20031103
ST cyclooxygenase inhibitor **migraine** treatment
IT Headache
(**migraine**; use of cyclooxygenase inhibitors for treating migraines)
IT 50-33-9, Phenylbutazone, biological studies 50-48-6, Amitriptyline 50-78-2, Aspirin 52-53-9, Verapamil 53-86-1, Indomethacin 54-21-7, Sodium salicylate 58-38-8, Prochlorperazine 60-79-7, Ergonovine 61-68-7, Mefenamic acid 62-49-7, Choline 99-66-1 113-15-5, Ergotamine 113-42-8, Methylergonovine 129-20-4, Oxyphenbutazone 361-37-5 364-62-5, Metoclopramide 511-08-0, Ergocristine 511-09-1, Ergocryptine 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-78-9, Flufenamic acid 552-94-3, Salsalate 561-94-4, Ergosine 599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 2854-38-8, Ergostine 8067-24-1, Ergoloid mesylates 13539-59-8, Apazone 13710-19-5, Tolfenamic acid 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 17479-19-5, Dihydroergocristine 17692-51-2, Metergoline 18917-89-0, Magnesium salicylate 20315-46-2, β Ergocryptine 21256-18-8, Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 25447-65-8, Dihydroergocornine 25447-66-9, Dihydroergocryptine 25614-03-3, Bromocriptine 26171-23-3, Tolmetin 29679-58-1, Fenoprofen 30544-47-9 34042-85-8, Sudoxicam 36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac 42924-53-8, Nabumetone 51803-78-2, Nimesulide 59804-37-4, Tenoxicam 70374-39-9, Lornoxicam 71125-38-7, Meloxicam 74103-06-3, Ketorolac 76866-93-8 87234-24-0, Cinnoxicam 162011-90-7, Rofecoxib **202409-33-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of cyclooxygenase inhibitors for treating migraines)

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:813958 CAPLUS
DN 137:316089
TI Oral pharmaceutical compositions comprising a low-water-soluble drug, a solvent, a fatty acid and an organic amine
Gao, Ping; Karim, Aziz; Hassan, Fred; Forbes, James C.

PA Pharmacia Corporation, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083177	A1	20021024	WO 2002-US11689	20020412 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2444220	AA	20021024	CA 2002-2444220	20020412 <--
	EP 1379279	A1	20040114	EP 2002-733979	20020412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008994	A	20040427	BR 2002-8994	20020412
	JP 2004530669	T2	20041007	JP 2002-580978	20020412
	NO 2003004629	A	20031210	NO 2003-4629	20031016
PRAI	US 2001-284381P	P	20010417		
	US 2001-326952P	P	20011004		
	WO 2002-US11689	W	20020412		

OS MARPAT 137:316089
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2002083177 A1 **20021024**

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083177	A1	20021024	WO 2002-US11689	20020412 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2444220	AA	20021024	CA 2002-2444220	20020412 <--
	EP 1379279	A1	20040114	EP 2002-733979	20020412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008994	A	20040427	BR 2002-8994	20020412
	JP 2004530669	T2	20041007	JP 2002-580978	20020412
	NO 2003004629	A	20031210	NO 2003-4629	20031016

IT Headache
(**migraine**; oral pharmaceutical compns. comprising low-water-soluble drug and solvent and fatty acid and organic amine)

IT 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 60-33-3, Linoleic acid, biological studies 69-89-6D, Xanthine, alkyl derivs. 77-86-1, Tromethamine 102-71-6, Triethanolamine, biological studies 108-01-0, Dimethylaminoethanol 111-42-2, Diethanolamine, biological studies 112-79-8, Elaidic acid 112-80-1, Oleic acid, biological studies 124-07-2, Octanoic acid,

biological studies 141-43-5, Monoethanolamine, biological studies 142-62-1, Caproic acid, biological studies 143-07-7, Lauric acid, biological studies 334-48-5, Capric acid 463-40-1, Linolenic acid 506-30-9, Eicosanoic acid 544-63-8, Myristic acid, biological studies 13296-76-9, Eleostearic acid 25322-68-3, Polyethylene glycol 32839-18-2 32839-30-8, Eicosapentaenoic acid 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 266320-83-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical compns. comprising low-water-soluble drug and solvent and fatty acid and organic amine)

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:555346 CAPLUS
DN 137:114529
TI Pharmaceutical composition having reduced tendency for drug crystallization
IN Gao, Ping; Hageman, Michael J.; Morozowich, Walter; Dalga, Robert J.; Stefanski, Kevin J.; Huang, Tiehua; Karim, Aziz; Hassan, Fred; Forbes, James C.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056878	A2	20020725	WO 2002-US971	20020115 <--
	WO 2002056878	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002156124	A1	20021024	US 2002-47902	20020114 <--
	CA 2434338	AA	20020725	CA 2002-2434338	20020115 <--
	US 2003045563	A1	20030306	US 2002-47222	20020115
	EP 1365812	A2	20031203	EP 2002-709027	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002006580	A	20031216	BR 2002-6580	20020115
	JP 2004520359	T2	20040708	JP 2002-557386	20020115
	NO 2003003244	A	20030917	NO 2003-3244	20030717
PRAI	US 2001-262555P	P	20010118		
	US 2001-284608P	P	20010417		
	WO 2002-US971	W	20020115		

OS MARPAT 137:114529
PI WO 2002056878 A2 **20020725**

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056878	A2	20020725	WO 2002-US971	20020115 <--
	WO 2002056878	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002156124	A1	20021024	US 2002-47902	20020114 <--
CA 2434338	AA	20020725	CA 2002-2434338	20020115 <--
US 2003045563	A1	20030306	US 2002-47222	20020115
EP 1365812	A2	20031203	EP 2002-709027	20020115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006580	A	20031216	BR 2002-6580	20020115
JP 2004520359	T2	20040708	JP 2002-557386	20020115
NO 2003003244	A	20030917	NO 2003-3244	20030717

IT Headache
(**migraine**; pharmaceutical composition having reduced tendency for drug crystallization)
IT 56-81-5, Glycerin, biological studies 58-08-2, Caffeine, biological studies 58-55-9, Theophylline, biological studies 69-89-6D, Xanthine, alkyl derivs. 83-67-0, Theobromine 9003-39-8, PVP 9004-32-4, Carboxymethyl cellulose sodium salt 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 25322-68-3, Polyethylene glycol 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 266320-83-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition having reduced tendency for drug crystallization)

L7 ANSWER 7 OF 14 USPATFULL on STN
AN 2002:315130 USPATFULL
TI Method of treating migraines and pharmaceutical compositions
IN Simitchieva, Kremena, Basking Ridge, NJ, UNITED STATES
Reines, Scott A., New Hope, PA, UNITED STATES
McKinney, Errol, Doylestown, PA, UNITED STATES
Sandquist, Eric J., Doylestown, PA, UNITED STATES
Khannna, Deepak K., Furlong, PA, UNITED STATES
Hargreaves, Richard, Terlings Park, UNITED KINGDOM
PA Merck & Co., Inc. (U.S. corporation)
PI US 2002177617 A1 20021128 <--
AI US 2002-106845 A1 20020326 (10)
RLI Division of Ser. No. US 2001-934823, filed on 22 Aug 2001, GRANTED, Pat. No. US 6384034 Continuation of Ser. No. US 1999-429274, filed on 29 Oct 1999, ABANDONED
PRAI US 1998-106605P 19981102 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002177617 A1 20021128 <--
AB A combination of a 5HT.sub.1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of **migraine**.
SUMM . . . has been known for some time that sumatriptan, which causes constriction of cranial blood vessels, is an effective treatment for **migraine** (see, for example, Doenicke et al., Lancet, 1988, Vol. 1, 1309-11; and Feniuk & Humphrey, Drug Development Research, 1992, 26,.

. .
SUMM . . . within the trigeminal nucleus caudalis. It is believed that one or more of these three mechanisms is involved in the anti-**migraine** action of 5-HT.sub.1B/1D receptor agonists such as rizatriptan.
SUMM . . . method of treating or preventing migraines in a mammalian patient in need thereof, which comprises administering to said patient an anti-**migraine** effective amount of a combination of a COX-2 selective inhibitor and a 5-HT.sub.1B/1D receptor agonist.
SUMM [0010] One embodiment of the present invention is a method of treating or preventing **migraine** with an anti-**migraine** effective amount of a combination of a 5HT.sub.1B/1D agonist and a COX-2 selective inhibitor. Another embodiment of the invention is. . .
SUMM [0015] In one aspect of the invention, a method of treating or preventing **migraine** is disclosed in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective. . .
SUMM [0024] An anti-**migraine** effective amount of the combination is that amount that will relieve the subject being treated of the symptoms of the **migraine** attack and the specific dose level and frequency of dosage may vary and will depend upon a variety of factors. . .
SUMM [0025] For the treatment of a **migraine** attack, the active ingredients, separately or in combination, may be administered orally, topically, parenterally, by inhalation, spray, rectally or intravaginally. . .
CLM What is claimed is:
1. A method of treating or preventing **migraine** in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective inhibiting compound. . .
IT 71125-38-7, Meloxicam 103628-46-2, Sumatriptan 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 145202-66-0, Rizatriptan benzoate 154323-57-6, Almotriptan 162011-90-7, Vioxx 169590-42-5, Celecoxib 179382-91-3, RS 57067 180200-69-5 **202409-33-4**, MK 663
(tablets containing histaminergic agonist and COX-2 inhibitor for migraine treatment)

L7 ANSWER 8 OF 14 USPATFULL on STN
AN 2002:221058 USPATFULL
TI Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
IN Le, Trang T., Mundelein, IL, UNITED STATES
Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Sastry, Srikonda V., Sunnyvale, CA, UNITED STATES
Nyshadham, Janaki R., Fremont, CA, UNITED STATES
Pagliero, Arthur J., JR., Vacaville, CA, UNITED STATES
PI US 2002119193 A1 20020829 <--
AI US 2001-932494 A1 20010817 (9)
PRAI US 2000-226349P 20000818 (60)
DT Utility
FS APPLICATION
LREP Pharmacia Corporation, Corporate Patent Dept., 800 N. Lindbergh Boulevard - 04B, St. Louis, MO, 63167
CLMN Number of Claims: 89
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002119193 A1 20020829 <--
SUMM [0061] Such compositions are useful in treating inflammation in such diseases as **migraine** headaches, periarteritis nodosa,

thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis,. . .

SUMM [0074] For pain management generally and specifically for treatment and prevention of headache and **migraine**, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to. . .

SUMM [0083] In an embodiment of the invention, particularly where the cyclooxygenase-2 mediated condition is headache or **migraine**, the present selective cyclooxygenase-2 inhibitory drug composition is administered in combination therapy with a vasomodulator, preferably a xanthine derivative having. . .

SUMM . . . vasomodulator or alkylxanthine are selected to be therapeutically and/or prophylactically effective for relief of pain associated with the headache or **migraine**. Suitable dosage amounts will depend on the particular selective cyclooxygenase-2 inhibitory drug and the particular vasomodulator or alkylxanthine selected. For. . .

IT 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 266320-83-6
(oral fast-melt formulation of cyclooxygenase-2 inhibitor)

L7 ANSWER 9 OF 14 USPATFULL on STN

AN 2002:199141 USPATFULL

TI Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor

IN Hariharan, Madhusudan, Evanston, IL, UNITED STATES
Kararli, Tugrul T., Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

PI US 2002107250 A1 20020808 <--

AI US 2001-836905 A1 20010417 (9)

PRAI US 2000-197746P 20000418 (60)

DT Utility

FS APPLICATION

LREP Pharmacia Corporation, P.O. Box 5110, Chicago, IL, 60680-5110

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002107250 A1 20020808 <--

AB . . . and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders, particularly pain. For relief of pain in headache or **migraine**, the composition can optionally be administered together with a vasodilator.

SUMM . . . disclose compositions comprising a selective COX-2 inhibitory drug, a 5HT.sub.1 receptor agonist and caffeine, said to be useful for treating **migraine**.

SUMM . . . immediate therapeutic effect than standard dosage forms. For example, in the treatment of acute pain, for example in headache or **migraine**, rapid-onset dosage forms would be useful to provide fast pain relief.

SUMM . . . important advance in the art to provide an effective method of treatment of acute pain, for example in headache or **migraine**, using such a formulation.

SUMM . . . selective COX-2 inhibitory drug composition of the invention. In another embodiment, a method of treatment and/or prevention of headache or **migraine** is provided comprising orally administering, to a subject in need of such treatment or prevention, an aminosulfonyl-comprising selective COX-2 inhibitory. . .
[0212] Such compositions are useful in treating inflammation in such

diseases as **migraine** headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis,. . .

DETD . . . for treatment of acute COX-2 mediated disorders, especially for relief of pain, for example in headache, including sinus headache and **migraine**.

DETD . . . surgery pain, post-general surgery pain, post-orthopedic surgery pain, and acute flares of osteoarthritis), for prevention and treatment of headache and **migraine**, for treatment of Alzheimer's disease, and for colon cancer chemoprevention.

DETD [0226] For pain management generally and specifically for treatment and prevention of headache and **migraine**, compositions of the invention can be used to provide a daily dose of celecoxib of about 50 mg to about. . .

DETD [0234] In an embodiment of the invention, particularly where the COX-2 mediated condition is headache or **migraine**, the present selective COX-2 inhibitory drug composition is administered in combination therapy with a vasomodulator, preferably a xanthine derivative having. . .

DETD . . . vasomodulator or alkylxanthine are selected to be therapeutically and/or prophylactically effective for relief of pain associated with the headache or **migraine**. Suitable dosage amounts will depend on the particular selective COX-2 inhibitory drug and the particular vasomodulator or alkylxanthine selected. For. . .

CLM What is claimed:

. . . cyclooxygenase-2 inhibitory drug and the vasomodulator are present in total and relative amounts effective to relieve pain in headache or **migraine**.

. . . inhibitory drug and the alkylxanthine compound are present in total and relative amounts effective to relieve pain in headache or **migraine**.

33. The method of claim 32 wherein the subject suffers from headache or **migraine** and wherein there is further orally administered to the subject a vasomodulator, the selective cyclooxygenase-2 inhibitory drug and the vasomodulator being administered in total and relative amounts effective to relieve pain in the headache or **migraine**.

35. The method of claim 32 wherein the subject suffers from headache or **migraine** and wherein there is further orally administered to the subject an alkylxanthine compound, the selective cyclooxygenase-2 inhibitory drug and the alkylxanthine compound being administered in total and relative amounts effective to relieve pain in the headache or **migraine**.

IT 58-08-2, Caffein, biological studies 58-55-9, Theophylline, biological studies 69-89-6D, Xanthine, alkyl derivs. 83-67-0, Theobromine 110-71-4, Ethylene glycol dimethyl ether 110-80-5, Ethylene glycol monoethyl ether 111-76-2, Ethylene glycol monobutyl ether 111-77-3, Diethylene glycol monomethyl ether 111-90-0, Diethylene glycol monoethyl ether 111-96-6, Diethylene glycol dimethyl ether 112-36-7, Diethylene glycol diethyl ether 112-48-1, Ethylene glycol dibutyl ether 112-49-2, Triethylene glycol dimethyl ether 112-50-5, Triethylene glycol monoethyl ether 112-73-2, Diethylene glycol dibutyl ether 122-99-6, Ethylene glycol monophenyl ether 124-07-2D, Caprylic acid, glycerides 143-22-6, Triethylene glycol monobutyl ether 143-24-8, Tetraethylene glycol dimethyl ether 334-48-5D, Capric acid, glycerides 622-08-2, Ethylene glycol monobenzyl ether 629-14-1, Ethylene glycol diethyl ether 764-99-8, Diethylene glycol divinyl ether 18912-80-6, Diethylene glycol monoisobutyl ether 37321-62-3, Propylene glycol

laurate 63980-40-5 68958-64-5, Polyoxyethylene glyceryl trioleate 156259-68-6, Capmul mcm 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 247074-38-0 266320-83-6
(rapid-onset formulation of selective cyclooxygenase-2 inhibitors)

L7 ANSWER 10 OF 14 USPATFULL on STN
AN 2002:149172 USPATFULL
TI Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
IN Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Skokie, IL, UNITED STATES
PI US 2002077328 A1 20020620 <--
AI US 2001-905292 A1 20010713 (9)
PRAI US 2001-296196P 20010606 (60)
US 2001-284248P 20010417 (60)
US 2000-218101P 20000713 (60)
DT Utility
FS APPLICATION
LREP SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102
CLMN Number of Claims: 125
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002077328 A1 20020620 <--
SUMM . . . disclose compositions comprising a selective COX-2 inhibitory drug, a 5HT.sub.1 receptor agonist and caffeine, said to be useful for treating **migraine**.
SUMM . . . immediate therapeutic effect than standard dosage forms. For example, in the treatment of acute pain, for example in headache or **migraine**, rapid-onset dosage forms would be useful to provide fast pain relief.
DETD . . . mechanisms giving rise to pain, especially headache pain. Under the vasogenic theory, intracranial vasoconstriction was responsible for the symptoms of **migraine** aura and headache resulted from a rebound dilation and distention of cranial vessels and activation of perivascular nociceptive axons. However, under the alternate nerogenic theory, the brain generates the **migraine** and susceptibility to **migraine** attacks reflects thresholds intrinsic to the individual's brain. Thus, vascular changes occurring during **migraine** are the result and not the cause of the attack. Even considering the alternate theories of **migraine**, vascular changes are implicated as an important event during the headache. Thus, using a vasomodulator to affect vascular changes in. . .
DETD . . . cyclooxygenase-2 inhibitor compound a vasomodulator, the pain can be generalized pain or headache pain. The headache pain can be from **migraine** headache pain, cluster headache pain, chronic daily headache pain, substance-induced headache pain, tension or stress related headache pain, sinus headache. . . arteritis, or headache pain resulting from lumbar puncture. A very important preference for this invention is pain which results from **migraine** pain. Another important preference in the present invention is pain resulting from a cluster headache. Another preferred source of pain. . .
CLM What is claimed:
11. The combination according claim 10 wherein the headache pain is selected from the group consisting of **migraine** headache pain, cluster headache pain, chronic headache pain, substance-induced headache pain, tension or stress related headache pain, sinus headache pain,. .
.
111. The method according to claim 106 wherein the pain is selected from

the group consisting of **migraine** headache pain, cluster headache pain, chronic headache pain, substance-induced headache pain, tension or stress related headache pain, sinus headache pain,. . .

IT 254-04-6D, Benzopyran, derivs. 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib 198470-84-7, Parecoxib **202409-33-4**, Etoricoxib 212126-32-4 266320-83-6
(cyclooxygenase 2 inhibitors for treatment and prevention of ocular COX-2-mediated disorders)

L7 ANSWER 11 OF 14 USPATFULL on STN
AN 2002:140876 USPATFULL
TI Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Le, Trang T., Mundelein, IL, UNITED STATES
PI US 2002071857 A1 20020613 <--
AI US 2001-932537 A1 20010817 (9)
PRAI US 2000-226487P 20000818 (60)
DT Utility
FS APPLICATION
LREP Pharmacia Corporation, Corporate Patent Dept., 800 N. Lindbergh Boulevard - 04B, St. Louis, MO, 63167
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002071857 A1 20020613 <--
DETD [0089] Such compositions are useful in treating inflammation in such diseases as **migraine** headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis,. . .
DETD [0102] For pain management generally and specifically for treatment and prevention of headache and **migraine**, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to. . .
DETD [0110] In an embodiment of the invention, particularly where the cyclooxygenase-2 mediated condition is headache or **migraine**, the present selective cyclooxygenase-2 inhibitory drug composition is administered in combination therapy with a vasomodulator, preferably a xanthine derivative having. . .
DETD . . . vasomodulator or alkylxanthine are selected to be therapeutically and/or prophylactically effective for relief of pain associated with the headache or **migraine**. Suitable dosage amounts will depend on the particular selective cyclooxygenase-2 inhibitory drug and the particular vasomodulator or alkylxanthine selected. For. . .
IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 57-27-2, Morphine, biological studies 57-42-1, Meperidine 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 76-57-3, Codeine 87-99-0, Xylitol 149-32-6, Erythritol 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, derivs. 9005-25-8, Starch, biological studies 9005-25-8D, Starch, derivs. 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 266320-83-6
(rapidly disintegrating oral formulation of cyclooxygenase-2 inhibitor)

L7 ANSWER 12 OF 14 USPATFULL on STN
AN 2002:92708 USPATFULL

TI Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Le, Trang T., Mundelein, IL, UNITED STATES
PI US 2002049233 A1 20020425 <--
AI US 2001-932500 A1 20010817 (9)
PRAI US 2000-226347P 20000818 (60)
DT Utility
FS APPLICATION
LREP Pharmacia Corporation, Corporate Patent Dept., 800 N. Lindbergh Boulevard - 04B, St. Louis, MO, 63167
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002049233 A1 20020425 <--
DETD [0049] Such compositions are useful in treating inflammation in such diseases as **migraine** headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis,. . .
DETD [0062] For pain management generally and specifically for treatment and prevention of headache and **migraine**, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to. . .
DETD [0069] In an embodiment of the invention, particularly where the cyclooxygenase-2 mediated condition is headache or **migraine**, the present selective cyclooxygenase-2 inhibitory drug composition is administered in combination therapy with a vasomodulator, preferably a xanthine derivative having. . .
DETD . . . vasomodulator or alkylxanthine are selected to be therapeutically and/or prophylactically effective for relief of pain associated with the headache or **migraine**. Suitable dosage amounts will depend on the particular selective cyclooxygenase-2 inhibitory drug and the particular vasomodulator or alkylxanthine selected. For. . .
IT 50-70-4, Sorbitol, biological studies 57-27-2, Morphine, biological studies 57-42-1, Meperidine 57-50-1, Sucrose, biological studies 57-55-6D, Propylene glycol, esters with fatty acids 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 76-57-3, Codeine 87-99-0, Xylitol 151-21-3, Sodium lauryl sulfate, biological studies 577-11-7, Dioctyl sodium sulfosuccinate 585-88-6, Maltitol 7631-86-9, Silica, biological studies 25301-02-4, Tyloxapol 25322-68-3D, Polyethylene glycol, derivs. 106392-12-5, Poloxamer 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 266320-83-6
(oral fast-melt formulation of cyclooxygenase-2 inhibitor)

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:780682 CAPLUS
DN 135:335155
TI Rapid-onset formulation of a selective cyclooxygenase-2 inhibitors
IN Hariharan, Madhusudan; Kararli, Tugrul T.; Hassan, Fred; Forbes, James C.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2001078724 A1 20011025 WO 2001-US12434 20010417 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2406226 AA 20011025 CA 2001-2406226 20010417 <--
US 2002107250 A1 20020808 US 2001-836905 20010417 <--
EP 1274425 A1 20030115 EP 2001-925050 20010417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004500427 T2 20040108 JP 2001-576024 20010417
PRAI US 2000-197746P P 20000418
WO 2001-US12434 W 20010417
OS MARPAT 135:335155
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2001078724 A1 **20011025**
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001078724 A1 20011025 WO 2001-US12434 20010417 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2406226 AA 20011025 CA 2001-2406226 20010417 <--
US 2002107250 A1 20020808 US 2001-836905 20010417 <--
EP 1274425 A1 20030115 EP 2001-925050 20010417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004500427 T2 20040108 JP 2001-576024 20010417

AB An orally deliverable pharmaceutical composition is provided comprising a selective cyclooxygenase-2 inhibitory drugs of low water solubility, for example celecoxib, and a glycol ether, for example diethylene glycol monoethyl ether. At least a substantial part of the drug is in dissolved or solubilized form in a solvent liquid comprising the glycol ether. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders, particularly pain. For relief of pain in headache or **migraine**, the composition can optionally be administered together with a vasodilator. Solubility of celecoxib and valdecoxib in various solvent liqs. was studied. A soft gelatin capsule contained celecoxib 200, Labrasol 280, diethylene glycol monoethyl ether 280, and propylene glycol laureate 140 mg.

IT 58-08-2, Caffein, biological studies 58-55-9, Theophylline, biological studies 69-89-6D, Xanthine, alkyl derivs. 83-67-0, Theobromine 110-71-4, Ethylene glycol dimethyl ether 110-80-5, Ethylene glycol monoethyl ether 111-76-2, Ethylene glycol monobutyl ether 111-77-3, Diethylene glycol monomethyl ether 111-90-0, Diethylene glycol monoethyl ether 111-96-6, Diethylene glycol dimethyl ether 112-36-7, Diethylene glycol diethyl ether 112-48-1, Ethylene glycol dibutyl ether 112-49-2, Triethylene glycol dimethyl ether 112-50-5, Triethylene glycol monoethyl ether 112-73-2, Diethylene glycol dibutyl ether 122-99-6, Ethylene glycol monophenyl ether 124-07-2D, Caprylic acid, glycerides 143-22-6,

Triethylene glycol monobutyl ether 143-24-8, Tetraethylene glycol dimethyl ether 334-48-5D, Capric acid, glycerides 622-08-2, Ethylene glycol monobenzyl ether 629-14-1, Ethylene glycol diethyl ether 764-99-8, Diethylene glycol divinyl ether 18912-80-6, Diethylene glycol monoisobutyl ether 37321-62-3, Propylene glycol laurate 63980-40-5 68958-64-5, Polyoxyethylene glyceryl trioleate 156259-68-6, Capmul mcm 162011-90-7, Rofecoxib 169590-41-4, Deracoxib 169590-42-5, Celecoxib 181695-72-7, Valdecoxib **202409-33-4**, Etoricoxib 212126-32-4 215123-80-1 247074-38-0 266320-83-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapid-onset formulation of selective cyclooxygenase-2 inhibitors)

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:314539 CAPLUS
DN 132:329940
TI Pharmaceutical compositions containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment
IN Simitchieva, Kremena; Reines, Scott A.; Mckinney, Errol; Sandquist, Eric J.; Khanna, Deepak K.; Hargreaves, Richard
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000025779	A1	20000511	WO 1999-US25388	19991029 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2348979	AA	20000511	CA 1999-2348979	19991029 <--
	EP 1126841	A1	20010829	EP 1999-960171	19991029 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002528498	T2	20020903	JP 2000-579220	19991029 <--
	AU 759307	B2	20030410	AU 2000-17098	19991029
	US 2002016348	A1	20020207	US 2001-934823	20010822 <--
	US 6384034	B2	20020507		
	US 2002177617	A1	20021128	US 2002-106845	20020326 <--
PRAI	US 1998-106605P	P	19981102		
	US 1999-429274	A1	19991029		
	WO 1999-US25388	W	19991029		
	US 2001-934823	A3	20010822		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Pharmaceutical compositions containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment
PI WO 2000025779 A1 **20000511**

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000025779	A1	20000511	WO 1999-US25388	19991029 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,				

SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2348979	AA	20000511	CA 1999-2348979	19991029 <--
EP 1126841	A1	20010829	EP 1999-960171	19991029 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528498	T2	20020903	JP 2000-579220	19991029 <--
AU 759307	B2	20030410	AU 2000-17098	19991029
US 2002016348	A1	20020207	US 2001-934823	20010822 <--
US 6384034	B2	20020507		
US 2002177617	A1	20021128	US 2002-106845	20020326 <--

AB A combination of a 5HT1B/1D agonist and a cyclooxygenase-2 (COX-2) selective inhibitor is useful in the treatment and/or prevention of **migraine**. The 5HT1B/1D agonist is selected from sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, and rizatriptan, and the COX-2 inhibitor is selected from meloxicam, MK-663, Vioxx, RS 57067, celecoxib, and compound I. The 5HT1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form or as sep. dosage forms administered concurrently. Tablets containing 5 and 10 mg of rizatriptan benzoate and 10 mg Vioxx were prepared

ST cyclooxygenase inhibitor histaminergic agonist tablet **migraine**

IT 5-HT agonists
(5-HT1B; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 5-HT agonists
(5-HT1D; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT Antimigraine agents
(tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT Drug delivery systems
(tablets; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 39391-18-9, Cyclooxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, inhibitors; tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

IT 71125-38-7, Meloxicam 103628-46-2, Sumatriptan 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 145202-66-0, Rizatriptan benzoate 154323-57-6, Almotriptan 162011-90-7, Vioxx 169590-42-5, Celecoxib 179382-91-3, RS 57067 180200-69-5 **202409-33-4**, MK 663
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tablets containing histaminergic agonist and COX-2 inhibitor for **migraine** treatment)

=>